The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
LLM 2021 | Using molecular techniques to define risk in patients with myeloma
Ruben Niesvizky, MD, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, gives an overview of a talk on using molecular techniques such as sequencing to define risk in patients with smoldering disease and extramedullary complications. These techniques will also help to better characterize these malignancies. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
